See the DrugPatentWatch profile for bosulif

Based on the information available, there are patents related to Bosulif's therapeutic uses. Bosulif, also known as bosutinib, is a medication used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1].

According to DrugPatentWatch.com, there are several patents related to Bosulif's therapeutic uses [2]. One such patent is the US Patent No. 8,669,193 B2, which covers the use of bosutinib for the treatment of cancer, including CML and Ph+ ALL [3]. This patent was issued in March 2014 and will expire in February 2032 [3].

Another patent related to Bosulif's therapeutic uses is the US Patent No. 9,181,924 B2, which covers the use of bosutinib in combination with other drugs for the treatment of cancer [4]. This patent was issued in November 2015 and will expire in November 2033 [4].

It is worth noting that these patents may affect the availability and cost of Bosulif for therapeutic uses. However, the specific impact of these patents on the market and patients is beyond the scope of this answer.

In summary, based on the available information from DrugPatentWatch.com, there are patents related to Bosulif's therapeutic uses, including the treatment of CML and Ph+ ALL.

Sources:
[1] Mayo Clinic. (2021). Bosutinib (Oral Route). Retrieved from <https://www.mayoclinic.org/drugs-supplements/bosutinib-oral-route/description/drg-20066531>.
[2] DrugPatentWatch.com. (2022). Bosutinib. Retrieved from <https://www.drugpatentwatch.com/drugs/bosutinib>.
[3] US Patent and Trademark Office. (2014). US Patent No. 8,669,193 B2. Retrieved from <https://pdfpiw.uspto.gov/.piw?PageNum=0&docid=09333332>.
[4] US Patent and Trademark Office. (2015). US Patent No. 9,181,924 B2. Retrieved from <https://pdfpiw.uspto.gov/.piw?PageNum=0&docid=09513622>.